Title: A short term clinical research about entecavir in treating 30 cases of HBeAg positive chronic hepatitis B
Abstract: Objective A study of short term efficacy and safety of entecavir(ETV)in chronic hepatitis B patients.Methods Thirty cases of HBeAg positive chronic hepatitis B were selected randomly as treatment group,and treated with ETV 0.5 mg daily for over 48 weeks.Another 30 cases of HBeAg positive chronic hepatitis were selected as observation group and treated with adefovir(ADV)10 mg daily for over 48 weeks.Patient's liver function,HBV DNA level,hepatitis B serology marker,renal function,and full blood count were assessed at 4 weeks,12 weeks and 24 weeks.!Results At 4 week,12 week and 24 weeks,the percentage of patients had undetectable HBV DNA in ETV group and ADV group were 57% versus 0%(P0.01),90% versus 57%(P0.5),93% versus 63%(P0.05),respectively.The percentage of patients achieving alanine aminotransferase normalization were 43% versus 20%(P0.05),77% versus 50%(P0.05),87% versus 73%(P0.05),respectively.HBeAg seroconversion rate in the two groups were 3% versus 0%(P0.05),3% versus 0%(P0.05),10% versus 0%(P0.05),respectively.There is no abnormal renal function observed in both groups.There was one case of neuthocytopenia(WBC 2.2×103/L)after 6 weeks in observation group which has been treated with Kushengsu with no further white cell reduction.Conclusions ETV can be used as first line antivirus drug in chronic hepatitis B as it has superior antiviral effects as well as HBeAg seroconversion than ADV in early stage.The group treated with ETV had higher rate of alanine aminotransferase normalization than the group treated with ADV.However,there is no significant difference.There were 3 cases in the ETV treated group who had HBeAg reduction after 24 weeks,but there was no one presented HBeAg seroconversion.There was no significant side effect observed in ETV treated group.
Publication Year: 2008
Publication Date: 2008-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot